Clinical Trial Update: Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the combination of fulvestrant with Zactima in postmenopausal women with bone-predominant, hormone receptor–positive metastatic breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• Zactima (vandetanib)

Snippet

Sponsor: Ontario Clinical Oncology Group (OCOG) | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED